Blocking the interaction of SDF-1 and its receptor CXCR4, by using the CXCR4 inhibitor AMD3100 or a CXCR4 neutralizing antibody, resulted in decreased tumor perfusion and an enhanced radioresponse of the glioma xenograft model. This evidence concerns the gene CXCL12 and central nervous system cancer.